Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells
OwnerSilviu ITESCUinventor
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods for treating or preventing Acute Respiratory Distress Syndrome (ARDS) in a subject in need thereof, the method comprising administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs).
Claims52
A method of treating Acute Respiratory Distress Syndrome (ARDS) in a human subject in need thereof, the method comprising selecting a subject with ARDS who is greater than or equal to 65 years old and, administering to the subject greater than 4 million mesenchymal lineage precursor or stem cells (MLPSCs) per kilogram of body weight (cells/kg).
A method of treating Acute Respiratory Distress Syndrome (ARDS) in a human subject in need thereof, the method comprising selecting a subject with ARDS who has increased inflammatory biomarkers which indicate:
- (a) increased neutrophil and macrophage influx into lungs;
- (b) increased macrophage inflammation and augmented neutrophil migration to lungs;
- and/or,
- (c) T cell activation/proliferation and apoptotic death, and, administering to the subject a greater than 4 million mesenchymal lineage precursor or stem cells (MLPSCs) per kilogram of body weight (cells/kg).
A method of treating or preventing Acute Respiratory Distress Syndrome (ARDS) in a human subject in need thereof, the method comprising:
- determining or having determined a subject's level of one or more inflammatory biomarkers selected from the list comprising:
- (i) a CXCR3 binding chemokine, preferably CXCL10, and/or CXCL9;
- (ii) a CCR2-binding chemokine, preferably CCL2, CCL3, and/or CCL7;
- (iii) IL-6;
- (v) IL-8;
- (vi) CCL19;
- (vii) IL-2;
- and/or (viii) CRP;
- selecting a subject who:
- is greater than or equal to 65 years old;
- and/or,
- has an increased level of one or more inflammatory biomarkers relative to a subject who is less than 65 years old;
- and/or,
- has persistent CRP levels 3 days after being administered a first dose of mesenchymal lineage precursor or stem cells (MLPSCs) which comprises less than 4 million MLPSCs per kilogram of body weight (cells/kg);
- and
- administering to the subject greater than 4 million mesenchymal lineage precursor or stem cells (MLPSCs) per kilogram of body weight (cells/kg).
A method of treating Acute Respiratory Distress Syndrome (ARDS) in a human subject in need thereof, the method comprising:
- administering to the subject 4 million mesenchymal lineage precursor or stem cells (MLPSCs) per kilogram of body weight (cells/kg);
- determining or having determined the subject's level of one or more biomarkers selected from the group consisting of CXCL10, CXCL9, CCL2, CCL3, CCL7, IL-6, IL-8, CCL19, IL-2, ferritin and/or CRP relative to a baseline level of the biomarker(s) prior to administering MLPSCs;
- administering a further dose of MLPSCs to the subject if the level of one or more biomarkers does not decrease from baseline, wherein following the further dose, the subject has been administered greater than 4 million mesenchymal lineage precursor or stem cells (MLPSCs) per kilogram of body weight (cells/kg).
Dependencies are inferred from the claim text.